<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00821483</url>
  </required_header>
  <id_info>
    <org_study_id>FRESH</org_study_id>
    <nct_id>NCT00821483</nct_id>
  </id_info>
  <brief_title>A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine</brief_title>
  <official_title>Phase 3 Study to Assess the Efficacy and Safety of Frovatriptan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:&#xD;
&#xD;
        1. To compare the efficacy of a single dose of Frovatriptan 2.5 mg with that of placebo in&#xD;
           acute treatment of up to one migraine attract&#xD;
&#xD;
        2. To assess recurrence rate between two group&#xD;
&#xD;
        3. To assess the safety and tolerability&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A comparison between Frovatriptan and placebo for the proportion of patients who have complete(grade 0) or almost complete(grade 1) relief of headache at 2 hours after taking Frovatriptan</measure>
    <time_frame>at 2 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">298</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>1: placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Frovatriptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Frovatriptan</intervention_name>
    <description>2.5mg, qd</description>
    <arm_group_label>1: placebo</arm_group_label>
    <arm_group_label>2 Frovatriptan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults aged 18 to 65 years&#xD;
&#xD;
          2. The patients must have a history of migraine according to the criteria of the Headache&#xD;
             Classification Committee of the International Headache Society(IHS), over the previous&#xD;
             1 year. The patient must have experienced one to eight moderate or severe migraine&#xD;
             attacks(with or without aura) each month over at least the previous two months&#xD;
&#xD;
          3. Onset of migraine disease must have occurred before the patients was 50 years of age&#xD;
&#xD;
          4. Able and willing to sign informed consent, and able and willing to comply with study&#xD;
             procedures, including the completion of diary cards.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating females, or women intend to become pregnant or breast feed&#xD;
             during the study period, or women of childbearing potential not using adequate&#xD;
             contraception. Females of reproductive potential must have a negative pregnancy test&#xD;
             at screening&#xD;
&#xD;
          2. Clinically significant renal dysfunction(creatinine≥2.0mg/dl) or hepatic&#xD;
             dysfunction(ALT,AST≥2 ULN)&#xD;
&#xD;
          3. Patients with clinically significant abnormal ECGs or with resting diastolic blood&#xD;
             pressure above 95mmHg&#xD;
&#xD;
          4. Patients with clinically significant cardiovascular or cerebrovascular disease&#xD;
&#xD;
          5. Patients with a history of clinically relevant allergy, including allergy to triptan&#xD;
&#xD;
          6. Previous treatment with Frovatriptan at any time or treatment with an investigational&#xD;
             drug within 30 days before screening visit&#xD;
&#xD;
          7. Patients with a diagnosis of vertebrobasilar or hemiplegic(prolonged atypical aura)&#xD;
             migraine(IHS criteria)&#xD;
&#xD;
          8. Potentially unco-operative patients, those unable to provide informed consent, and&#xD;
             those unable to complete the diary&#xD;
&#xD;
          9. patients who habitually abuse headache medication including ergotamine-containing&#xD;
             compounds, and patients with a history of alcohol and/or medicine abuse, in the&#xD;
             Investigator's opinion&#xD;
&#xD;
         10. Patients who are not able to tell that they are having a migraine headache&#xD;
&#xD;
         11. Patients who have 15 or more headache days per month, on average, or those taking&#xD;
             symptomatic medication for headaches on more than two days per week, on average&#xD;
&#xD;
         12. Treatment with a monoamine-oxidase inhibitor(MAOI) within two weeks of the screening&#xD;
             visit&#xD;
&#xD;
         13. Patients who are taking prophylactic migraine medication, unless dose has been&#xD;
             stabilized for 30 days and it expected to continue for the duration of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun U Kwon, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Asan Medical Center, University of Ulsan</affiliation>
  </overall_official>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>January 12, 2009</study_first_submitted>
  <study_first_submitted_qc>January 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2009</study_first_posted>
  <last_update_submitted>April 16, 2013</last_update_submitted>
  <last_update_submitted_qc>April 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Frovatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

